Amphetamine

Koniku and Airbus Expand Partnership to Re-imagine Aviation Security

Retrieved on: 
Wednesday, July 20, 2022
Software, Defense, Other Defense, Hardware, Technology, Air, Transport, Security, Virus, KTIE, Amphetamine, Aviation, Reading, CEO, Silicon, SoftBank Group, Organic compound, Partnership, Solution, Health, Travel, Intensive animal farming, Safety, Multimedia, Fentanyl, Robotics, Machine learning, Biotechnology, Platform capitalism, Technology, Map, Transport, Atmosphere, Life, Investment, Mark (given name), Engineering, Food safety, IOT, Synthetic biology, Nose, Airline, Airbus

The Airbus leadership team, including Airbus Corporate Security, has repeatedly reinforced to Koniku the paramount importance of passenger security, safety, and positive experience on the ground and at 30,000 feet, said Osh.

Key Points: 
  • The Airbus leadership team, including Airbus Corporate Security, has repeatedly reinforced to Koniku the paramount importance of passenger security, safety, and positive experience on the ground and at 30,000 feet, said Osh.
  • This collaboration will allow Airbus to explore the development of advanced biotechnology solutions capable of revolutionizing aviation and airport security, for the benefit of both passengers and aviation transportation security officials, said Jeff Knittel, Airbus Americas Inc. Chairman, and CEO.
  • This partnership is the latest phase in an ongoing cooperation agreement between Koniku and Airbus, which began in 2017.
  • Koniku and Airbus have performed multiple successful tests and performance validations in partnership with local and federal law enforcement agencies and airport security operations.

New Start Recovery Solutions Monterey Open July 1, 2022 - Dual Diagnosis Addiction Recovery in Beautiful Monterey California

Retrieved on: 
Friday, June 17, 2022
MAKE, LIFE, Yoga, Amphetamine, NEW, Monterey Bay, Beacon House, Queen Anne, North Jersey Pediatric and Adult Nursing and Wellness Center, Addiction, Lefferts Historic House, Meditation, Patient, Pine Manor, Florida, Queen Anne, Seattle, Historic house, Mindfulness, Beacon House and Grove Cottage, Monterey Peninsula, Hospital, Risk management, Interior design

MONTEREY, Calif., June 17, 2022 /PRNewswire-PRWeb/ -- New Start Recovery Solutions is proud to announce the July opening of New Start Recovery Solutions Monterey.

Key Points: 
  • We believe that addiction is a complex but treatable disease and that a 'universal' addiction treatment program is not appropriate for everyone.
  • Dual diagnosis addiction recovery treatment at New Start Recovery Solutions Monterey includes detox , individual counseling, group counseling and individualized medication protocol (when needed).
  • Addiction recovery patients in our elegant yet home-like Monterey facility will experience sea breezes, serenity and healing.
  • The opening of New Start Recovery Solutions Monterey at 468 Pine Ave, Pacific Grove, CA in July 2022 will mark the public return of a Monterey historic home.

Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering

Retrieved on: 
Friday, May 13, 2022
4th floor, Form, Company, Narcolepsy, U.S. Securities and Exchange Commission, Ladenburg Thalmann, Patient, NASDAQ, SEC filing, Regulation D, Fifth Avenue, Central nervous system disease, FDA, Report, Securities Act of 1933, CNS, Amphetamine, ADHD, Forward-looking statement, Central nervous system, Sale, LinkedIn, Twitter, Acquisition, SEC, Growth, The Act, Prospectus, Security (finance), GLOBE, Pharmaceutical industry

Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering.

Key Points: 
  • Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering.
  • Vallon intends to use the net proceeds from the financing for general corporate and working capital purposes and expenses associated with the exploration of strategic alternatives.
  • Such shares of common stock may be offered only by means of a prospectus, including a prospectus supplement.
  • Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA.

Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR

Retrieved on: 
Thursday, May 12, 2022
Vital signs, Abuse, Company, Dextroamphetamine, History, Narcolepsy, Șaeș, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Attention deficit hyperactivity disorder, U.S. Securities and Exchange Commission, AUC, Wireless ambulatory ECG, Patient, NASDAQ, Review, Cmax, Sexual abuse, Central nervous system disease, FDA, Report, CNS, Amphetamine, ADHD, Forward-looking statement, Central nervous system, Safety, Table, SEAL, LinkedIn, PD, Twitter, Acquisition, Growth, GLOBE, CEO, Tmax, Pharmaceutical industry, Generic drug, Medical imaging, Dietary supplement, Vallon, Pharmacokinetics

The SEAL study enrolled 55 subjects, of whom 53 completed the study and 52 were included in the final analysis.

Key Points: 
  • The SEAL study enrolled 55 subjects, of whom 53 completed the study and 52 were included in the final analysis.
  • The study involved a four-way crossover design to evaluate professionally manipulated, intranasal ADAIR 30 mg, crushed intranasal dextroamphetamine, ADAIR 30 mg taken orally, and placebo.
  • Vallon has completed its initial analysis of the full data set and has received final tables, figures, and listings for the study.
  • The overall safety and tolerability profile of ADAIR in the SEAL study was consistent with the well-established profile of dextroamphetamine.

Vallon Pharmaceuticals Announces Issuance of Japanese Patent Covering Composition of Matter and Methods of Manufacturing for ADAIR

Retrieved on: 
Wednesday, May 11, 2022
Forward-looking statement, Narcolepsy, Report, Twitter, U.S. Securities and Exchange Commission, Dextroamphetamine, NASDAQ, GLOBE, CNS, Company, Food, ADHD, Central nervous system disease, Patient, Acquisition, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patent, Japan Patent Office, LinkedIn, Method, Growth, Abuse, Central nervous system, Pharmaceutical industry, Amphetamine

7054709 titled, Abuse Deterrent Formulations of Amphetamine, covering ADAIR 1, the Companys proprietary abuse-deterrent formulation of immediate-release dextroamphetamine.

Key Points: 
  • 7054709 titled, Abuse Deterrent Formulations of Amphetamine, covering ADAIR 1, the Companys proprietary abuse-deterrent formulation of immediate-release dextroamphetamine.
  • David Baker, President & Chief Executive Officer of Vallon commented, The Japanese market is one of the fastest growing markets for prescription ADHD medications.
  • As we continue to evaluate the best path forward for our novel abuse-deterrent formulation of dextroamphetamine, ADAIR, we are pleased to expand its global intellectual property portfolio.
  • The new Japanese patent covers composition of matter and methods of manufacturing for ADAIR, with a base patent term extending until 2038.

Psychemedics Corporation Reports First Quarter 2022 Financial Results and Declares Increased Cash Dividend

Retrieved on: 
Tuesday, May 10, 2022
Board, COVID-19, Board of directors, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Record, NASDAQ, GLOBE, Forgiveness, Company, Cocaine, Drug overdose, ERC, School, Fentanyl, Security (finance), Urine, FDA, Psychemedics Corporation, Compliance, Benzodiazepine, Abuse, Government, Amphetamine, Death, R, Income, Federal Reserve Bank, Paycheck Protection Program, Transport, Director, Growth, Risk, PMD, Online gambling, Video game, Management, Pharmaceutical industry

The Companys revenue for the quarter ended March 31, 2022, was $6.5 million versus $5.7 million for the quarter ended March 31, 2021, an increase of 14%.

Key Points: 
  • The Companys revenue for the quarter ended March 31, 2022, was $6.5 million versus $5.7 million for the quarter ended March 31, 2021, an increase of 14%.
  • Raymond C. Kubacki, Chairman and Chief Executive Officer, stated:
    "We are off to a strong start in the first quarter of 2022.
  • In addition, operating expenses for the first quarter of 2022 were flat compared to the first quarter of 2021.
  • Therefore, earnings per share for the first quarter of 2022 were also flat compared to the first quarter of 2021, despite no ERC recorded in 2022.

Vallon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, May 9, 2022
Board, Forward-looking statement, Narcolepsy, Report, Twitter, U.S. Securities and Exchange Commission, NASDAQ, GLOBE, CNS, PD, Company, Sexual abuse, Methylphenidate, Safety, Research, Ladenburg Thalmann, ADHD, Central nervous system disease, Patient, Amphetamine, D&O, FDA, LinkedIn, Attention deficit hyperactivity disorder, Growth, Central nervous system, Acquisition, SEAL, Pharmaceutical industry, Vallon, Pharmacokinetics

PHILADELPHIA, PA, May 09, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (Vallon or the Company), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the quarter ended March 31, 2022 and provided a corporate update.

Key Points: 
  • PHILADELPHIA, PA, May 09, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (Vallon or the Company), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the quarter ended March 31, 2022 and provided a corporate update.
  • The first quarter of this year proved to be challenging for Vallon with the unexpected, disappointing topline results from our pivotal SEAL study evaluating ADAIR.
  • This process is now underway, and we plan to identify the best pathway forward for Vallon in order to build shareholder value in the near and long term.
  • In March 2022, the Company reported topline results from its SEAL study (Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation).

Vallon Pharmaceuticals Announces Review of Strategic Alternatives

Retrieved on: 
Friday, April 22, 2022
U.S. Securities and Exchange Commission, Ladenburg, Twitter, NASDAQ, CNS, Methylphenidate, GLOBE, ADHD, Patient, LinkedIn, Growth, Company, Attention deficit hyperactivity disorder, Amphetamine, Forward-looking statement, Narcolepsy, Central nervous system disease, Ladenburg Thalmann, FDA, Acquisition, Report, SEAL, Pharmaceutical industry

Ladenburg has been engaged to advise Vallon on the strategic review process, which could include, without limitation, exploring the potential for a possible merger, business combination, investment into the Company, or a purchase, license or other acquisition of assets.

Key Points: 
  • Ladenburg has been engaged to advise Vallon on the strategic review process, which could include, without limitation, exploring the potential for a possible merger, business combination, investment into the Company, or a purchase, license or other acquisition of assets.
  • Thompson Hine LLP serves as Vallons legal counsel and will assist with the exploration of alternatives.
  • In the meantime, and in conjunction with the exploration of strategic alternatives, the Company is streamlining its operations in order to preserve its capital and cash resources.
  • Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA.

Vallon Pharmaceuticals to Participate at the 5th Annual Neuroscience Innovation Forum

Retrieved on: 
Wednesday, March 23, 2022
Company, LinkedIn, NASDAQ, Amphetamine, CNS, CEO, Twitter, GLOBE, Narcolepsy, ADHD, Central nervous system disease, Patient, Pharmaceutical industry, Online shopping, Vallon

Philadelphia, PA, March 23, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, announced today that David Baker, President & Chief Executive Officer of Vallon will participate at the virtual 5th Annual Neuroscience Innovation Forum on the “Advances in Neuropsychiatry” panel, being held today, March 23, 2022, at 9:00 AM ET. A live webcast of the panel will be accessible to those registered to attend the conference.

Key Points: 
  • A live webcast of the panel will be accessible to those registered to attend the conference.
  • Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA.
  • The Company is focused on the development of new medications to help patients with CNS disorders.
  • For more information about the company, please visit www.vallon-pharma.com or connect with us on LinkedIn or Twitter .

Workforce Drug Test Positivity Climbs to Highest Level in Two Decades, Finds Quest Diagnostics Drug Testing Index Analysis

Retrieved on: 
Wednesday, March 30, 2022
People, U.S. Department of Defense Strategy for Operating in Cyberspace, Urine, Map, Drug, Heroin, Aircraft, Government, Transport, Particle-size distribution, Multimedia, Health care, Power plant engineering, NYSE, National Safety Council, Plasma protein binding, Adult, NSC, Doctor of Philosophy, Accident, ZIP, General manager, Methamphetamine, Hospital, Welfare, Conference, DTI, Health, Oxycodone, Retail, Solution, Workforce, Industry, Quest Diagnostics, Safety, Cocaine, Database, Collection, Hair, Physician, Amphetamine, DGX, Department, Morale, Foodservice, Workplace, Medical device, Ridesharing company, Lithium, Health insurance, Pharmaceutical industry, Animal

SECAUCUS, N.J., March 30, 2022 /PRNewswire/ -- The rate of positive drug test results among America's workforce reached its highest rate last year since 2001 and was up more than 30% in the combined U.S. workforce from an all-time low in 2010-2012, according to a new analysis released today by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services.

Key Points: 
  • For an interactive map of the Drug Testing Index with positivity rates and trend lines by drug categories and three-digit ZIP code inthe United States, visitDTIDrugMap.com.
  • "Our Drug Testing Index data raises important questions about what it means to be an employer committed to employee health and safety.
  • The new findings of the Quest Diagnostics Drug Testing Index are being unveiled this week at the Drug & Alcohol Testing Association 2022 Conference taking placeMarch 30-April 2inLouisville, KY.
  • Quest Diagnostics is the leading workforce drug testing provider, offering a broad range of drug testing options that allow employers to combine and customize a drug testing program that meets their unique business needs, all from a single, convenient provider.